Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833963 · ClinicalTrials.gov registry record
A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine
A clinical trial, sponsored by Genentech.
- Completed
- Registry status
- 20
- Enrollment target
NCT00833963 is a clinical trial that has completed, run by Genentech. The registered enrollment target is 20 participants.
The verdict
NCT00833963 has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The MotHER Pregnancy Registry is a United States (U.S.)-based, prospective, observational cohort study in women with breast cancer who have been or are being treated with a trastuzumab (herceptin)-containing regimen with or without pertuzumab (perjeta) or ado-trastuzumab emtansine (kadcyla) during pregnancy or within 7 months prior to conception (regardless of cancer stage at the time of trastuzumab, pertuzumab, or ado-trastuzumab emtansine exposure).
Interventions
- DRUG Trastuzumab
- DRUG Pertuzumab
- DRUG Ado-Trastuzumab Emtansine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-01-14 |
| Est. Completion | 2017-04-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833963
The ClinicalTrials.gov registry entry for NCT00833963 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT00833963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00833963 about?
NCT00833963 is a clinical study titled "A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine". The MotHER Pregnancy Registry is a United States (U.S.)-based, prospective, observational cohort study in women with breast cancer who have been or are being treated with a trastuzumab (herceptin)-containing regimen with or without pertuzumab (perjeta) or ado-trastuzumab emtansine (kadcyla) during p...
What is the current status of trial NCT00833963?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2009-01-14. Estimated completion is 2017-04-13.
What interventions are being tested in trial NCT00833963?
The interventions under investigation include: Trastuzumab (DRUG), Pertuzumab (DRUG), Ado-Trastuzumab Emtansine (DRUG).
Who is sponsoring clinical trial NCT00833963?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.